Literature DB >> 15180492

Cytochrome P450 in neurological disease.

M Liu1, P D Hurn, N J Alkayed.   

Abstract

Advances in a multitude of disciplines support an emerging role for cytochrome P450 enzymes and their metabolic substrates and end-products in the pathogenesis and treatment of central nervous system disorders, including acute cerebrovascular injury, such as stroke, chronic neurodegenerative disease, such as Alzheimer's and Parkinson's disease, as well as epilepsy, multiple sclerosis and psychiatric disorders, including anxiety and depression. The neural tissue contains its own unique set of P450 genes that are regulated in a manner that is distinct from their molecular regulation in peripheral tissue. Furthermore, brain P450s catalyze the formation of important brain signaling molecules, such as neurosteroids and eicosanoids, and metabolize substrates as diverse as vitamins A and D, cholesterol, bile acids, as well as centrally acting drugs, anesthetics and environmental neurotoxins. These unique characteristics allow this family of proteins and their metabolites to perform such vital functions in brain as neurotrophic support, neuroprotection, control of cerebral blood flow, temperature control, neuropeptide release, maintenance of brain cholesterol homoeostasis, elimination of retinoids from CNS, regulation of neurotransmitter levels and other functions important in brain physiology, development and disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15180492     DOI: 10.2174/1389200043335540

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  20 in total

1.  A novel method for assessing sex-specific and genotype-specific response to injury in astrocyte culture.

Authors:  Mingyue Liu; Esteban A Oyarzabal; Rui Yang; Stephanie J Murphy; Patricia D Hurn
Journal:  J Neurosci Methods       Date:  2008-03-18       Impact factor: 2.390

Review 2.  Neuroprotection of sex steroids.

Authors:  M Liu; M H Kelley; P S Herson; P D Hurn
Journal:  Minerva Endocrinol       Date:  2010-06       Impact factor: 2.184

3.  Sex- and isoform-specific mechanism of neuroprotection by transgenic expression of P450 epoxygenase in vascular endothelium.

Authors:  Jia Jia; Catherine M Davis; Wenri Zhang; Matthew L Edin; Sari Jouihan; Taiping Jia; J Alyce Bradbury; Joan P Graves; Laura M DeGraff; Craig R Lee; Oline Ronnekleiv; Ruikang Wang; Yun Xu; Darryl C Zeldin; Nabil J Alkayed
Journal:  Exp Neurol       Date:  2016-02-20       Impact factor: 5.330

4.  Sex differences in ischemic stroke sensitivity are influenced by gonadal hormones, not by sex chromosome complement.

Authors:  Bharti Manwani; Kathryn Bentivegna; Sharon E Benashski; Venugopal Reddy Venna; Yan Xu; Arthur P Arnold; Louise D McCullough
Journal:  J Cereb Blood Flow Metab       Date:  2014-11-12       Impact factor: 6.200

5.  Soluble epoxide hydrolase inhibitor trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid is neuroprotective in rat model of ischemic stroke.

Authors:  Jafar Sadik B Shaik; Muzamil Ahmad; Wenjin Li; Marie E Rose; Lesley M Foley; T Kevin Hitchens; Steven H Graham; Sung Hee Hwang; Bruce D Hammock; Samuel M Poloyac
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-09-16       Impact factor: 4.733

6.  Inhibition of soluble epoxide hydrolase preserves cardiomyocytes: role of STAT3 signaling.

Authors:  Matthias J Merkel; Lijuan Liu; Zhiping Cao; William Packwood; Jennifer Young; Nabil J Alkayed; Donna M Van Winkle
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-12-11       Impact factor: 4.733

Review 7.  Mechanisms of gender-linked ischemic brain injury.

Authors:  Mingyue Liu; Suzan Dziennis; Patricia D Hurn; Nabil J Alkayed
Journal:  Restor Neurol Neurosci       Date:  2009       Impact factor: 2.406

8.  Expression and distribution of CYP3A genes, CYP2B22, and MDR1, MRP1, MRP2, LRP efflux transporters in brain of control and rifampicin-treated pigs.

Authors:  Annalisa Nannelli; Francesco Rossignolo; Roberto Tolando; Paolo Rossato; Mario Pellegatti; Vincenzo Longo; P Giovanni Gervasi
Journal:  Mol Cell Biochem       Date:  2009-10-22       Impact factor: 3.396

9.  Soluble epoxide hydrolase gene deletion reduces survival after cardiac arrest and cardiopulmonary resuscitation.

Authors:  Michael P Hutchens; Takaaki Nakano; Jennifer Dunlap; Richard J Traystman; Patricia D Hurn; Nabil J Alkayed
Journal:  Resuscitation       Date:  2007-08-28       Impact factor: 5.262

10.  Soluble epoxide hydrolase gene deletion is protective against experimental cerebral ischemia.

Authors:  Wenri Zhang; Takashi Otsuka; Nobuo Sugo; Ardi Ardeshiri; Yazan K Alhadid; Jeffrey J Iliff; Andrea E DeBarber; Dennis R Koop; Nabil J Alkayed
Journal:  Stroke       Date:  2008-03-27       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.